What is William Blair’s Forecast for Medpace Q2 Earnings?

Medpace Holdings, Inc. (NASDAQ:MEDP) – Equities research analysts at William Blair lowered their Q2 2025 earnings estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, April 22nd. William Blair analyst M. Smock now forecasts that the company will earn $3.02 per share for the quarter, down from their previous forecast of $3.09. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. William Blair also issued estimates for Medpace’s FY2025 earnings at $12.45 EPS, Q3 2026 earnings at $3.11 EPS, Q4 2026 earnings at $3.05 EPS and FY2026 earnings at $12.45 EPS.

Several other research firms have also commented on MEDP. Truist Financial reduced their price target on shares of Medpace from $333.00 to $300.00 and set a “hold” rating on the stock in a research report on Wednesday. Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a report on Wednesday, April 9th. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th. TD Cowen lowered shares of Medpace from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Finally, Robert W. Baird dropped their target price on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating for the company in a report on Wednesday. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Medpace presently has an average rating of “Hold” and a consensus target price of $349.30.

Medpace Price Performance

MEDP stock opened at $298.55 on Friday. Medpace has a 1 year low of $250.05 and a 1 year high of $459.77. The firm has a market capitalization of $9.02 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The business has a 50 day simple moving average of $313.79 and a 200-day simple moving average of $331.70.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same quarter last year, the business posted $3.20 earnings per share.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently modified their holdings of the company. Bartlett & CO. Wealth Management LLC boosted its position in shares of Medpace by 17.5% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 343 shares of the company’s stock worth $105,000 after acquiring an additional 51 shares in the last quarter. Bessemer Group Inc. lifted its stake in Medpace by 1.1% during the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company’s stock worth $177,411,000 after purchasing an additional 6,225 shares during the last quarter. Moran Wealth Management LLC acquired a new position in Medpace in the first quarter valued at approximately $5,158,000. Sheets Smith Wealth Management increased its stake in Medpace by 4.6% in the first quarter. Sheets Smith Wealth Management now owns 3,289 shares of the company’s stock valued at $1,002,000 after purchasing an additional 144 shares during the last quarter. Finally, Ausbil Investment Management Ltd acquired a new stake in Medpace during the first quarter worth approximately $601,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.